141 related articles for article (PubMed ID: 25339453)
1. MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.
Ge X; Zheng L; Huang M; Wang Y; Bi F
Mol Med Rep; 2015 Jan; 11(1):333-40. PubMed ID: 25339453
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.
Hu Y; Qin X; Yan D; Cao H; Zhou L; Fan F; Zang J; Ni J; Xu X; Sha H; Liu S; Yu S; Wu J; Ma R; Feng J
Tumour Biol; 2017 Mar; 39(3):1010428317691659. PubMed ID: 28345454
[TBL] [Abstract][Full Text] [Related]
3. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
[TBL] [Abstract][Full Text] [Related]
4. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
[TBL] [Abstract][Full Text] [Related]
5. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
6. Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.
Sin TK; Wang F; Meng F; Wong SC; Cho WC; Siu PM; Chan LW; Yung BY
Int J Mol Sci; 2016 Feb; 17(2):237. PubMed ID: 26891293
[TBL] [Abstract][Full Text] [Related]
7. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
Ni J; Zhou LL; Ding L; Zhao X; Cao H; Fan F; Li H; Lou R; Du Y; Dong S; Liu S; Wang Z; Ma R; Wu J; Feng J
Exp Cell Res; 2017 Dec; 361(2):246-256. PubMed ID: 29080795
[TBL] [Abstract][Full Text] [Related]
8. [Screening and identification of microRNAs related to acquired gefitinib-resistance in lung adenocarcinoma cell lines].
Qin X; Liu B; Li Y; You J; Zhou Q
Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):478-83. PubMed ID: 21645449
[TBL] [Abstract][Full Text] [Related]
9. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells.
Li H; Zhang P; Sun X; Sun Y; Shi C; Liu H; Liu X
Int J Oncol; 2015 Oct; 47(4):1379-92. PubMed ID: 26323677
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.
Kim JH; Ahn JH; Lee M
Cancer Res Treat; 2017 Oct; 49(4):947-959. PubMed ID: 28052651
[TBL] [Abstract][Full Text] [Related]
12. Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway.
Zhou J; Qu G; Zhang G; Wu Z; Liu J; Yang D; Li J; Chang M; Zeng H; Hu J; Fang T; Song Y; Bai C
J Exp Clin Cancer Res; 2019 Feb; 38(1):96. PubMed ID: 30791926
[TBL] [Abstract][Full Text] [Related]
13. The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance.
Gong J; He L; Ma J; Zhang J; Wang L; Wang J
J BUON; 2017; 22(2):454-461. PubMed ID: 28534369
[TBL] [Abstract][Full Text] [Related]
14. [Differential expression of serum miRNAs in patients with advanced non-small cell lung cancer treated by gifitinib before and after acquiring drug resistance].
Huang Q; Li D
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Dec; 43(12):1288-1293. PubMed ID: 30643043
[TBL] [Abstract][Full Text] [Related]
15. Expression Profiles of microRNAs in Drug-Resistant Non-Small Cell Lung Cancer Cell Lines Using microRNA Sequencing.
Hu S; Yuan Y; Song Z; Yan D; Kong X
Cell Physiol Biochem; 2018; 51(6):2509-2522. PubMed ID: 30557872
[TBL] [Abstract][Full Text] [Related]
16. 5-Aza-CdR can reverse gefitinib resistance caused by DAPK gene promoter methylation in lung adenocarcinoma cells.
Yang B; Yang ZG; Gao B; Shao GG; Li GH
Int J Clin Exp Pathol; 2015; 8(10):12961-6. PubMed ID: 26722491
[TBL] [Abstract][Full Text] [Related]
17. FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells.
Xu N; Zhang X; Wang X; Ge HY; Wang XY; Garfield D; Yang P; Song YL; Bai CX
Acta Pharmacol Sin; 2012 May; 33(5):675-81. PubMed ID: 22447226
[TBL] [Abstract][Full Text] [Related]
18. The long non-coding RNA SNHG5 regulates gefitinib resistance in lung adenocarcinoma cells by targetting
Wang Z; Pan L; Yu H; Wang Y
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29592872
[TBL] [Abstract][Full Text] [Related]
19. [Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib].
Wang Q; Li M; Hu C
Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):193-8. PubMed ID: 25936882
[TBL] [Abstract][Full Text] [Related]
20. The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
Lee Y; Choi YR; Kim KY; Shin DH
Oncotarget; 2016 Jul; 7(28):43315-43323. PubMed ID: 27270313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
